Biotherapeutics Startup GentiBio Receives $157 mln in Series A Round


GentiBio raised about $157 million in Series A led by Matrix Capital Management. It is an emerging and Boston-based MA biotherapeutic company. At present, GentiBio is working on the development of T-cell-modulating therapies (Tregs) which are designed for immunology.

GentiBio’s co-founders are pioneers in Treg biology as well as synthetic immunology.

The Series A round counted the participation of investors like OrbiMed, Avidity Partners, JDRF T1D Fund, RA Capital Management, and the Seattle Children’s Research Institute.

GentiBio has completely and exclusively designed its Tregs platform itself with the aim of overcoming limitations in T-cell therapy. The company is a leader in solving problems caused by diseases which include overactivity or troubled immune systems.

With this investment, GentiBio will advance the functional treatment of Type 1 Diabetes (T1D). At the same time, many other pipeline programs in chronic autoimmune and autoimmune disease will also be promoted.

In August 2020, GentiBio was officially established with investments from OrbiMed, Novartis Venture Fund and RA Capital worth $20 million. The company was launched as a biotherapeutic company to treat diseases such as autoimmune, allergic, auto-inflammatory or allergic conditions.

GentiBio has leveraged its platform to diversify the Treg phenotype, and is looking for ways to scale up its solutions to a much larger scale.

Led by M.D., M.S., President and CEO, Adel Nada, GentiBio is currently selecting clinical candidates for its T1D trials and will begin conducting studies in support of IND by December of this year.

There are numerous opportunities in novel medical treatments. The recent fundraising by this company shows that when a good technology has promise, it will find capital to support its growth.

While many media outlets have been laser-focused on the COVID19 outbreak, established medical conditions, like T1D, create huge costs, and loss of life, on an annual basis. The work being done by GentiBio may also find solutions to other common problems over the coming years. 

Source